



## Settlement of Biolife Science Qld Ltd Acquisition

---

**Melbourne, 20 December 2013:** Australian drug development and pharmaceutical company Imugene (ASX:IMU) is pleased to report that the settlement of the acquisition of Biolife Science Qld Ltd ("Biolife") has taken place following the satisfaction of various conditions including IMU shareholder approvals received on the 20<sup>th</sup> December 2013, completion of due diligence, and the key vendors and Imugene complying with all their obligations under the Share Sale Agreement.

Also approved by shareholders, Dr Axel Hoos (Global VP Oncology R&D at GlaxoSmithKline) has joined the board as non-executive director. Mr Steve Harris has resigned as non-executive chairman effective immediately and current non-executive director Mr Paul Hopper becomes executive chairman. Mr Harris has made an invaluable contribution to the Company as a director and has provided dedicated leadership as Chairman of the company. The company acknowledges Steve's significant contribution to Imugene and wishes him well in his future endeavours.

300,000,000 shares have been issued as consideration of the acquisition of Biolife in accordance with resolution 3 approved by shareholders at the General Meeting on 20<sup>th</sup> December 2013. The shares issued to the key vendors are subject to 12 months escrow.

**-ends**

**Contact :**

Dr Nick Ede, Imugene on 0400 642 254 or nede[at]imugene.com

**Media contact:**

Dr Douglas Pretsell, College Hill – +61 3 9657 0706 / douglas.pretsell[at]collegehill.com

For more information please visit [www.imugene.com](http://www.imugene.com) or follow Imugene on Facebook

For personal use only